

Xiaohua Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3482818/publications.pdf>

Version: 2024-02-01

93
papers

2,361
citations

236925

25
h-index

254184

43
g-index

94
all docs

94
docs citations

94
times ranked

3399
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 97.e1-97.e16. | 1.3 | 20 |
| 2 | Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 653-661. | 7.0 | 10 |
| 3 | Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. , 2022, 10, e003831. | | 18 |
| 4 | The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. <i>BMC Surgery</i> , 2022, 22, 81. | 1.3 | 3 |
| 5 | A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 39. | 3.0 | 12 |
| 6 | Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , . | 1.1 | 4 |
| 7 | Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. <i>Cancer Treatment Reviews</i> , 2022, 106, 102385. | 7.7 | 44 |
| 8 | Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 550. | 2.6 | 19 |
| 9 | Niraparib treatment for patients with <i>BRCA</i> -mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536. | 2.4 | 4 |
| 10 | Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2021, 14, 12. | 3.0 | 13 |
| 11 | An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2452-2458. | 7.0 | 27 |
| 12 | Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 364-364. | 1.7 | 4 |
| 13 | BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. <i>Oncogene</i> , 2021, 40, 2711-2724. | 5.9 | 36 |
| 14 | FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. <i>Molecular Cancer</i> , 2021, 20, 45. | 19.2 | 69 |
| 15 | Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia. <i>Frontiers in Oncology</i> , 2021, 11, 643986. | 2.8 | 5 |
| 16 | HNRNP1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway. <i>Oncogene</i> , 2021, 40, 4770-4782. | 5.9 | 10 |
| 17 | Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 687899. | 2.8 | 5 |
| 18 | Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855. | 1.6 | 183 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Abstract 2044: Genomic scar score: a robust model to predict recombination repair deficient based on genomic instability. , 2021, , . | | 1 |
| 20 | Retrotransposons: Jump to Cancer?. Trends in Cancer, 2021, 7, 577-579. | 7.4 | 2 |
| 21 | Diagnostic accuracy of 18F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3392-3398. | 2.0 | 8 |
| 22 | Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. Clinical and Translational Medicine, 2021, 11, e500. | 4.0 | 34 |
| 23 | Reoperation with Total Hysterectomy after Incomplete Surgery Is Helpful in Patients with Incidentally Diagnosed Uterine Leiomyosarcoma. Gynecologic and Obstetric Investigation, 2021, 86, 408-414. | 1.6 | 0 |
| 24 | Extraperitoneal laparoscopy for para-aortic lymphadenectomy in endometrial carcinoma staging: an approach with higher efficiency. World Journal of Surgical Oncology, 2021, 19, 323. | 1.9 | 6 |
| 25 | Extracellular vesicle-derived miR-320a targets ZC3H12B to inhibit tumorigenesis, invasion, and angiogenesis in ovarian cancer. Discover Oncology, 2021, 12, 51. | 2.1 | 4 |
| 26 | Predictive value of preoperative serum squamous cell carcinoma antigen (SCC-Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study. European Journal of Surgical Oncology, 2020, 46, 131-138. | 1.0 | 18 |
| 27 | The role of 18F-FDG PET/CT-based quantitative metabolic parameters in patients with ovarian clear cell carcinoma. Cancer Biomarkers, 2020, 27, 189-194. | 1.7 | 4 |
| 28 | circCELSR1 (hsa_circ_0063809) Contributes to Paclitaxel Resistance of Ovarian Cancer Cells by Regulating FOXR2 Expression via miR-1252. Molecular Therapy - Nucleic Acids, 2020, 19, 718-730. | 5.1 | 91 |
| 29 | Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis. Gynecologic Oncology, 2020, 156, 357-362. | 1.4 | 5 |
| 30 | A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer. Frontiers in Oncology, 2020, 10, 571671. | 2.8 | 3 |
| 31 | Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. Journal of Ovarian Research, 2020, 13, 89. | 3.0 | 16 |
| 32 | Clinicopathologic and survival analysis of patients with adenoid cystic carcinoma of vulva: single-institution experience. International Journal of Clinical Oncology, 2020, 25, 2144-2150. | 2.2 | 4 |
| 33 | Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma. Journal of Surgical Oncology, 2020, 122, 538-546. | 1.7 | 4 |
| 34 | Metastatic patterns do not provide additional prognostic information for patients with FIGO stage IV high-grade serous ovarian cancer. Journal of Surgical Oncology, 2020, 122, 315-319. | 1.7 | 1 |
| 35 | Circ0004390 promotes cell proliferation through sponging miR-198 in ovarian cancer. Biochemical and Biophysical Research Communications, 2020, 526, 14-20. | 2.1 | 20 |
| 36 | Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses. Cancer Management and Research, 2020, Volume 12, 5213-5223. | 1.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. <i>Cancer Medicine</i> , 2020, 9, 5899-5907. | 2.8 | 9 |
| 38 | Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases. <i>Cancer Management and Research</i> , 2020, Volume 12, 913-919. | 1.9 | 6 |
| 39 | Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer. <i>Thrombosis Research</i> , 2020, 190, 129-134. | 1.7 | 8 |
| 40 | Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 632195. | 2.8 | 3 |
| 41 | ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6106-TPS6106. | 1.6 | 6 |
| 42 | Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. <i>Aging</i> , 2020, 12, 11398-11415. | 3.1 | 12 |
| 43 | The development of a homologous recombination deficiency (HRD) score to identify HR-deficient tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, e18085-e18085. | 1.6 | 1 |
| 44 | Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 6032-6032. | 1.6 | 0 |
| 45 | Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase III trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 6034-6034. | 1.6 | 1 |
| 46 | Appendiceal mucinous neoplasm mimics ovarian tumors: Challenges for preoperative and intraoperative diagnosis and clinical implication. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2120-2125. | 1.0 | 19 |
| 47 | Ovarian cancer circulating extracellular vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis. <i>BMC Cancer</i> , 2019, 19, 1095. | 2.6 | 17 |
| 48 | Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1244-1251. | 2.5 | 19 |
| 49 | Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. <i>International Journal of Oncology</i> , 2019, 54, 1719-1733. | 3.3 | 78 |
| 50 | Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5025-5036. | 3.6 | 37 |
| 51 | Telomere length in cervical exfoliated cells, interaction with HPV genotype, and cervical cancer occurrence among high-risk HPV-positive women. <i>Cancer Medicine</i> , 2019, 8, 4845-4851. | 2.8 | 6 |
| 52 | 18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications. <i>BMC Cancer</i> , 2019, 19, 226. | 2.6 | 8 |
| 53 | Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis. <i>Translational Cancer Research</i> , 2019, 8, 1217-1223. | 1.0 | 2 |
| 54 | ERBB2 mutation: A promising target in non-squamous cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 311-316. | 1.4 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin $\alpha 4$ /SNAI1/SIRT3 signaling pathway. <i>Oncogene</i> , 2018, 37, 4164-4180. | 5.9 | 91 |
| 56 | Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6647-6656. | 2.0 | 28 |
| 57 | The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 883. | 2.6 | 52 |
| 58 | Mutational analysis of KRAS and its clinical implications in cervical cancer patients. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e4. | 2.2 | 25 |
| 59 | A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e65. | 2.2 | 27 |
| 60 | Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC). <i>Journal of Ovarian Research</i> , 2017, 10, 7. | 3.0 | 15 |
| 61 | Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2017, 147, 589-596. | 1.4 | 25 |
| 62 | Downregulation of eukaryotic initiation factor 4A1 improves radiosensitivity by delaying DNA double strand break repair in cervical cancer. <i>Oncology Letters</i> , 2017, 14, 6976-6982. | 1.8 | 6 |
| 63 | The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1650-1657. | 2.5 | 60 |
| 64 | Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma. <i>BMC Cancer</i> , 2017, 17, 317. | 2.6 | 13 |
| 65 | miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 562-568. | 1.8 | 24 |
| 66 | Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e77. | 2.2 | 46 |
| 67 | Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. <i>PLoS ONE</i> , 2017, 12, e0170879. | 2.5 | 29 |
| 68 | Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. <i>Oncotarget</i> , 2017, 8, 32848-32855. | 1.8 | 10 |
| 69 | Predictive factors of para-aortic lymph nodes metastasis in cervical cancer patients: a retrospective analysis based on 723 para-aortic lymphadenectomy cases. <i>Oncotarget</i> , 2017, 8, 51840-51847. | 1.8 | 30 |
| 70 | Menstrual pattern after abdominal radical trachelectomy. <i>Oncotarget</i> , 2017, 8, 53146-53153. | 1.8 | 11 |
| 71 | Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e62. | 2.2 | 14 |
| 72 | Advances in diagnosis and treatment of metastatic cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e43. | 2.2 | 338 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e18. | 2.2 | 24 |
| 74 | Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. <i>Current Treatment Options in Oncology</i> , 2016, 17, 44. | 3.0 | 28 |
| 75 | Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 466-470. | 1.4 | 31 |
| 76 | The Survival Rate and Surgical Morbidity of Abdominal Radical Trachelectomy Versus Abdominal Radical Hysterectomy for Stage IB1 Cervical Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2953-2958. | 1.5 | 24 |
| 77 | A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. <i>Scientific Reports</i> , 2016, 6, 25408. | 3.3 | 47 |
| 78 | Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. <i>BMC Cancer</i> , 2016, 16, 43. | 2.6 | 37 |
| 79 | The effect of visceral obesity on clinicopathological features in patients with endometrial cancer: a retrospective analysis of 200 Chinese patients. <i>BMC Cancer</i> , 2016, 16, 209. | 2.6 | 20 |
| 80 | Adjuvant concurrent chemoradiation followed by chemotherapy for high-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 58-63. | 1.4 | 10 |
| 81 | Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer. <i>PLoS ONE</i> , 2016, 11, e0156101. | 2.5 | 39 |
| 82 | Abdominal scar characteristics as a predictor of cervical stenosis after abdominal radical trachelectomy. <i>Oncotarget</i> , 2016, 7, 37755-37761. | 1.8 | 7 |
| 83 | PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. <i>Scientific Reports</i> , 2015, 5, 14035. | 3.3 | 35 |
| 84 | Conization Using an Electrosurgical Knife for Cervical Intraepithelial Neoplasia and Microinvasive Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0131790. | 2.5 | 21 |
| 85 | Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. <i>Oncotarget</i> , 2015, 6, 4968-4975. | 1.8 | 44 |
| 86 | RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells. <i>Cancer Cell International</i> , 2015, 15, 41. | 4.1 | 6 |
| 87 | Incidence, risk factors and treatment of cervical stenosis after radical trachelectomy: A systematic review. <i>European Journal of Cancer</i> , 2015, 51, 1751-1759. | 2.8 | 56 |
| 88 | A new method of surgical margin assuring for abdominal radical trachelectomy in frozen section. <i>European Journal of Cancer</i> , 2015, 51, 734-741. | 2.8 | 7 |
| 89 | Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population. <i>Gynecologic Oncology</i> , 2015, 137, 274-279. | 1.4 | 10 |
| 90 | CASP7 variants modify susceptibility to cervical cancer in Chinesewomen. <i>Scientific Reports</i> , 2015, 5, 9225. | 3.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 91 | A novel highly sensitive and specific flow cytometry system for cervical cancer screening. <i>Gynecologic Oncology</i> , 2015, 139, 52-58. | 1.4 | 10 |
| 92 | Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. <i>Nature Communications</i> , 2014, 5, 4682. | 12.8 | 59 |
| 93 | Mutational analysis of <i>KRAS</i> and its clinical implications in cervical cancer patients. <i>Journal of Gynecologic Oncology</i> , 0, 29, . | 2.2 | 0 |